Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2009

View Archived Issues

Final data reported from phase Ib trial of atacicept in pretreated CLL patients

Romiplostim safe and effective in phase I/II study in pediatric ITP patients

Preliminary phase I safety and efficacy of IMGN-901 seen in pretreated MM patients

Novel TGR5 receptor agonists identified by AstraZeneca for type 2 diabetes treatment

Chroma Therapeutics describes novel Plk-1 inhibitors for cancer therapy

BMS identifies novel nAChR agonists

Biovitrum advances novel long-acting factor VIII-based hemophilia A therapy

FDA approves newly revised prescribing information for Teva's Azilect

Warner Chilcott affirms agreement with sanofi-aventis

Clinical data on candesartan in diabetic retinopathy disclosed at ISOPT

Pilot trial data indicate beneficial effects of Copaxone in dry AMD

Vorinostat in combination with tamoxifen safe and effective in phase II breast cancer trial

Daiichi Sankyo presents novel antibacterial compounds

Columbia University identifies VMAT2 ligands for the treatment of diabetes

Sanofi Pasteur expands study of Clostridium difficile vaccine to the U.S.

Celgene reports topline clinical phase IIb data on apremilast in psoriasis

Once-weekly exenatide superior to Byetta in type 2 diabetes patients

Nippon Shinyaku launches Erizas in Japan for the treatment of allergic rhinitis

Adcirca tablets launched by Nippon Shinyaku for pulmonary arterial hypertension

NDA submitted by Nippon Shinyaku for azacitidine in myelodysplastic syndromes

Novartis submits MAA to EMEA for Joulferon for hepatitis C

Primary endpoints unmet in Gilead's phase III darusentan trial in resistant hypertension

Lytix Biopharma obtains approval in Norway and Sweden for phase I trial of LTX-315

AstraZeneca and University of Virginia to collaborate on CAD and PDA therapies

Evotec receives milestone payment from Ono under collaboration on protease inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...